Fig 4. Comparison of survival, clinical GVHD score, and tumor burden among GVHD, GVL with/without PTCY treatment (100, 200, and 400 mg/kg) and leukemia mouse models.

The mice were allocated to one of the following six groups: GVHD, GVL, leukemia, and PTCY at doses of 100, 200, and 400 mg/kg (n = 6 each). The mice were observed daily for survival following transplantation and every other day to calculate their clinical GVHD scores (A). Bioluminescence imaging with photons (line graphs in the middle row) for each group and the status of the mice were observed for 50 days following transplantation (B).